MIT-184

N/A

Report date: 2025/01/26 17:18:22
NME

Base Information

Drug NameMIT-184
Drug Alias NameRet tyrosine kinase receptor inhibitor (Novartis Institutes for Biomedical research)MIT-184
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor RET inhibitors
TargetsTyrosine-protein kinase receptor RET
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Institutes For Biomedical Research Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Institutes For Biomedical Research Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A